Navigation Links
OXiGENE Abstracts Published in ASCO Program

l M. Patterson of the Mount Vernon Cancer Centre indicates that while the study had not yet reached maximum tolerated dose and recruitment is ongoing, the data to date suggest that OXi4503 is tolerated at doses up to 5 mg/m2 without dose-limiting toxicity. Changes in functional activity, as assessed with DCI-MRI and PET imaging evaluations, were observed in three of the eleven patients studied. OXi4503 is a novel, second-generation vascular disrupting agent with potential intrinsic cytotoxicity exerted through an ortho-quinone metabolite. The drug candidate is being evaluated in this Phase I dose escalation and safety study. Based on results to date, OXiGENE currently anticipates initiating further clinical studies with OXi4503 in 2007.

About Combretastatin A4 Phosphate/CA4P (ZYBRESTAT) and OXi4503

ZYBRESTAT is poised to become the first therapeutic product in a novel class of small-molecule drug candidates called vascular disrupting agents (VDAs). The Company currently anticipates starting a Phase II/III pivotal registration study with ZYBRESTAT in June 2007 under a Special Protocol Assessment agreement with the US Food and Drug Administration. Via interaction with vascular endothelial cell cytoskeletal proteins, ZYBRESTAT selectively targets and collapses tumor vasculature, thereby depriving the tumor of oxygen and causing death of tumor cells. ZYBRESTAT has demonstrated potent and selective activity against tumor vasculature, as well as substantial clinical activity against ATC and other solid tumors in clinical studies to date. Our strategy for optimizing the antitumor activity of ZYBRESTAT is to combine it with other types of therapeutic modalities, including cytotoxic drugs, anti-angiogenesis drugs, and radiation therapy. The rationale for combining ZYBRESTAT with other therapeutic modalities stems from the hypothesis that agents with different and potentially complimentary mechanisms of action and with a non-overlapping toxicity profile may achi
'"/>




Page: 1 2 3 4

Related medicine technology :

1. OXiGENE Announces a Poster Presentation Highlighting Results from its Study of ZYBRETSTAT CA4P in Myopic Macular Degeneration (Study MMD-213) at the 47th Annual Meeting of the Association of Research in Vision and Ophthalmology
2. Savient Pharmaceuticals Announces Acceptance of Two Gout-Related Abstracts for Poster Presentation at the European League Against Rheumatism (EULAR) 2007 Annual Congress
3. Six Abstracts Featuring Exelixis Compounds Accepted At ASCO Conference
4. Genta Incorporated to Present Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
5. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
6. SciClone Announces ZADAXIN and SCV-07 Abstracts Accepted at ASCO
7. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
8. New Proof of Genisteins Efficacy and Safety for Osteopenia and Osteoporosis Published in Annals of Internal Medicine
9. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
10. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
11. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: OXiGENE Abstracts Published ASCO Program
(Date:8/1/2014)... LAWRENCE, Mass. , Aug. 1, 2014  NxStage Medical, ... innovative dialysis products, today announced that Jeffrey H. Burbank ... Financial Officer, will present at the 34 th Annual ... Boston, MA , on Wednesday, August 13 ... event will be made available at http://ir.nxstage.com/ .  ...
(Date:8/1/2014)... JUPITER, Fla. , Aug. 1, 2014 ... company whose patented and proprietary technologies are used to ... the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, ... for the second quarter ended June 30, 2014 after ... host a conference call that day at 5:00 p.m. ...
(Date:7/31/2014)... , July 31, 2014  According to data ... Services, the 2015 average monthly Medicare Part D premium ... far lower than was originally projected, the Pharmaceutical Care ... D program continues to be a bright spot in ... choices in each region and using cutting edge, cost-saving ...
Breaking Medicine Technology:NxStage to Present at the 34th Annual Canaccord Genuity Growth Conference 2Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 2Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 3
... GeneXpert(R) System ... ... today announced the U.S. Food & Drug Administration (FDA) categorized,Cepheid,s ... Clinical Laboratory Improvement Amendments (CLIA).,The new test is designed for ...
... Michael J. Fox,Foundation today announced the availability of ... toward transformative treatments and a cure for,Parkinson,s disease., ... researchers through the,Foundation,s Pipeline Programs, five separate initiatives ... drug development pipeline. This includes,early-stage discovery research, translational ...
Cached Medicine Technology:Cepheid Molecular Diagnostic Test for Positive Blood Culture Bottles Categorized 'Moderate Complexity' by FDA 2Cepheid Molecular Diagnostic Test for Positive Blood Culture Bottles Categorized 'Moderate Complexity' by FDA 3Cepheid Molecular Diagnostic Test for Positive Blood Culture Bottles Categorized 'Moderate Complexity' by FDA 4Michael J. Fox Foundation Announces $11 Million in 2009 Funding for Translational, Pre-Clinical and Clinical Parkinson's Disease Research 2Michael J. Fox Foundation Announces $11 Million in 2009 Funding for Translational, Pre-Clinical and Clinical Parkinson's Disease Research 3Michael J. Fox Foundation Announces $11 Million in 2009 Funding for Translational, Pre-Clinical and Clinical Parkinson's Disease Research 4
(Date:8/1/2014)... This week marks a significant milestone ... week of paying commissions to its independent distributor sales ... January 2005 total $1,405,954,677.06. , MonaVie distributors can be ... pays commissions in 18 different currencies, including: AUD, EUR, ... PLN, USD, SGD, KRW, TWD, THB and GBP. ...
(Date:8/1/2014)... A leading dress supplier, Discount-Dress.com, explores a variety of ... any lady’s wardrobe fashionable and exciting. Recently, the company has ... To attract more people, it is now launching a special ... to 65% off. , “Summer is the season of short ... to our collection of ‘ 2014 summer short styles .’ ...
(Date:8/1/2014)... August 01, 2014 Transparency Market ... the addition of a comprehensive report on the ... System Market (Large Volume, Disposable, Syringe, Ambulatory and ... Trends And Forecast, 2013 – 2019’ is now ... http://www.transparencymarketresearch.com . , To begin with, the report ...
(Date:8/1/2014)... CentraComm, a leading managed IT security ... the Pure Storage® Authorized Reseller program. , ... experience designed to meet the rigorous resiliency, scalability, ... diverse markets, and for a variety of high ... years. , The Pure Storage FlashArray was ...
(Date:8/1/2014)... HealthDay Reporter THURSDAY, July 31, 2014 ... Africa has a well-earned reputation as one of the world,s ... intense medical care can greatly improve a person,s chances of ... wreaks life-threatening havoc within the body by attacking multiple organ ... back on the basics of "good meticulous intensive care," supporting ...
Breaking Medicine News(10 mins):Health News:MonaVie Records 500th Commission Week, Having Paid Out More Than $1.4B in Distributor Commissions 2Health News:Discount-Dress.com’s Top Trend Report: 2014 Summer Short Bridesmaid Dresses Now for Sale 2Health News:Transparency Market Research Adds Report on Global Infusion System Market to its Repository 2Health News:Transparency Market Research Adds Report on Global Infusion System Market to its Repository 3Health News:CentraComm Accepts Pure Storage Authorized Reseller Partner Invitation 2Health News:CentraComm Accepts Pure Storage Authorized Reseller Partner Invitation 3Health News:There's No Ebola Cure, But Early Intensive Treatment Boosts Survival 2Health News:There's No Ebola Cure, But Early Intensive Treatment Boosts Survival 3
... Lifeclinic International is this year,s Gold Sponsor of the Harvard Business ... Joseph B. Martin Conference Center, Harvard Medical School, November 6 - ... ... 2008 -- Lifeclinic International, Inc. , the world,s leading manufacturer ...
... Jazz,Pharmaceuticals, Inc. (Nasdaq: JAZZ ) announced today ... On Tuesday, November 11, 2008 at 2:50 p.m. ... a corporate presentation at the,Rodman & Renshaw 10th Annual ... November 12, 2008 at 3:30 p.m. MST (5:30 p.m. ...
... Product Will Be Sold by A Uniquely-Trained Sales ... ... Group plc,(LSE: PSK) today announced that SANCUSO(R) (Granisetron Transdermal System),is now available ... States. Sancuso was approved by,the U.S. Food and Drug Administration (F.D.A.) in ...
... have vaccination rates far below goals, study finds , , ... adolescents with asthma and other high-risk illnesses are getting ... vaccination rates from 1992 to 2002 for 18,703 adolescents ... conditions. , During the study period, vaccination rates improved, ...
... Fifteen Abstracts Will Be Featured at ASN, ... a leading,provider of kidney care services for those ... DaVita Clinical Research(R) (DCR),recently contributed fifteen abstracts to ... American Society of Nephrology. These,abstracts were developed both ...
... Nov. 4 The Quantum Group,Inc. (Amex: ... today that Noel J. Guillama, President & Chief ... Annual Westergaard,Conference on November 12, 2008. Mr. Guillama ... and Chief Technology & Innovations Officer,and Ron Smith, ...
Cached Medicine News:Health News:Lifeclinic International Lead Sponsor at Harvard Business School Health Conference 2Health News:SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Chemotherapy Patients, Now Available 2Health News:SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Chemotherapy Patients, Now Available 3Health News:Too Many High-Risk Teens Not Getting Flu Shots 2Health News:DaVita Abstracts Accepted into American Society of Nephrology Meeting 2Health News:DaVita Abstracts Accepted into American Society of Nephrology Meeting 3Health News:DaVita Abstracts Accepted into American Society of Nephrology Meeting 4Health News:The Quantum Group Inc. To Present at Paulson Investment's 31st Annual Westergaard Conference 2Health News:The Quantum Group Inc. To Present at Paulson Investment's 31st Annual Westergaard Conference 3
Ballard trach care HMES and filters, tv 1500, HME with built-in flex tube...
Indications For Usage: ,Single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended to be replaced at least once every 24 hours...
... The Portex® Thermovent® T helps provide protection to ... is small and extremely lightweight making it ideal ... With a high rate of heat and moisture ... retention., ,All HMEs and filters have ISO ...
... helps provide protection to the exposed airway of ... lightweight making it ideal for active young children ... of heat and moisture recovery, it ensures patient ... and filters have ISO standard tapered ends to ...
Medicine Products: